September 2014

CRANBURY, N.J., Sept. 9, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2014.  Fiscal Year Ended June 30, 2014 and Recent …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results Read More »

CRANBURY, N.J., Sept. 4, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2014 operating results on Tuesday, September 9, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 9, …

Palatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2014 Results Read More »

CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: “Palatin”) and Gedeon Richter Plc. (hereinafter: “Richter”) announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional …

Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter Read More »